TRDA News and Press, Entrada Therapeutics Inc. From 03/13/24

– Cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 – – Completed dosing for third cohort of Phase 1 clinical trial of ENTR-601-44 for the po...

Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...

2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...

Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...

2024-02-21 10:50:27 ET More on Entrada Therapeutics Entrada Therapeutics promotes Dowden to President Seeking Alpha’s Quant Rating on Entrada Therapeutics Historical earnings data for Entrada Therapeutics Financial information for Entrada Therapeutics ...

2024-02-13 06:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-03 07:49:10 ET More on Entrada Therapeutics Entrada says FDA declined to lift clinical hold on Duchenne candidate Seeking Alpha’s Quant Rating on Entrada Therapeutics Historical earnings data for Entrada Therapeutics Financial information for E...

- With a proven track record at Entrada and across his 30-year career in the healthcare sector, Mr. Dowden is well-positioned to help continue driving Entrada’s operational growth - BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical...

2023-12-28 06:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-22 12:41:46 ET More on Mid-day movers stock. BioVie: Upcoming Phase 3 Readout In Alzheimer's May Create Significant Value BioVie: Bullish Signals From Blinded Data Presentation (Rating Upgrade) BioVie: Well-Powered Phase 3 Trial In Alzheimer's Could Greatly B...